Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239564 | 1.00 | GRM5 (0.37) | GRM5FFAR1PDE4DALKPDE4A | |
| SCHEMBL15261948 | 0.87 | GRM5 (0.42) | GRM5FFAR1PDE4DALKPDE4A | |
| SCHEMBL15262160 | 0.87 | GRM5 (0.42) | GRM5FFAR1PDE4DALKPDE4A | |
| SCHEMBL15261947 | 0.87 | GRM5 (0.42) | GRM5FFAR1PDE4DALKPDE4A | |
| SCHEMBL16239342 | 0.82 | GRM5 (0.41) | GRM5FFAR1PDE4DPDE4APDE4B | |
| SCHEMBL16239340 | 0.82 | GRM5 (0.41) | GRM5FFAR1PDE4DPDE4APDE4B | |
| SCHEMBL18471221 | 0.78 | GRM5 (0.46) | GRM5P2RX3P2RX2AKT1PIK3CA | |
| SCHEMBL22911177 | 0.78 | GRM5 (0.46) | GRM5P2RX3P2RX2AKT1PIK3CA | |
| SCHEMBL18471226 | 0.78 | GRM5 (0.46) | GRM5P2RX3P2RX2AKT1PIK3CA | |
| SCHEMBL15262629 | 0.78 | SYK (0.41) | GRM5FFAR1P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2803664-B1 | TETRAHYDROBENZOFURANE DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF DIABETES | JIANGSU HENGRUI MEDICINE CO (CN) | 2018-11-21 | — | — | EP | disclosed |
| US-9139548-B2 | Polycyclic derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| US-9139548-B2 | Polycyclic derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| US-9139548-B2 | Polycyclic derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| US-20150005282-A1 | POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-01-01 | — | — | US | disclosed |
| US-20150005282-A1 | POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-01-01 | — | — | US | disclosed |
| US-20150005282-A1 | POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-01-01 | — | — | US | disclosed |
| EP-2803664-A1 | POLYCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005282-A1 | POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | GPR119, GPR55, GPR65 | GRM5 209/4885FFAR1 19/4885PDE4D 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.